Oxford BioMedica (OXB) has signed a collaboration and licence agreement with haemophilia specialist Bioverativ. The agreement allows the US-based company – which was recently bought by French pharma giant Sanofi – access to OXB’s LentiVector platform, which will be used to help develop a novel treatment for haemophilia.
IC TIP:
Hold
at
12p
OXB will receive $5m (£3.6m) upfront and various milestone payments, potentially worth $100m.